KathleenMMahoneyMD

PubMed

• 1 citations
  Regulation of HHLA2 expression in kidney cancer and myeloid cells.
  Tomonari Shigemura, Nahuel Perrot, Zimo Huang, Rupal S Bhatt, Aseman Bagheri Sheshdeh, Nourhan El Ahmar, Fatme Ghandour, Sabina Signoretti, David F McDermott, Gordon J...> ;BMC Cancer. 2023 Oct 27
• 10 citations
  Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.
  Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, Anna Seto, Marianna Zavodovskaya, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Susa...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
• 1 citations
  Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
  Randolph J Noelle, J Louise Lines, Lionel D Lewis, Robert E Martell, Thierry Guillaudeux, Sam W Lee, Kathleen M Mahoney, Matthew D Vesely, Jerome Boyd-Kirkup, Dhanya K...> ;Frontiers in Oncology. 2023 Jan 1
• 32 citations
  Soluble PD-L1 as an early marker of progressive disease on nivolumab.
  Kathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind-Rotolo, David F McDermott, F Stephen Hodi, Toni K Choueiri, Gordon J Freeman> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
• 4 citations
  Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses.
  Xia Bu, Vikram R. Juneja, Carol Reynolds, Kathleen M. Mahoney, Melissa T. Bu, Kathleen A. McGuire, Seth Maleri, Ping Hua, Baogong Zhu, Sarah R. Klein, Edward A. Greenf...> ;Cancer Immunology Research. 2021 Oct 11
• 203 citations
  Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Cancer Cell. 2021 May 10
• 6 citations
  Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.
  Irving D. Kaplan, Glenn J. Bubley, Rupal S. Bhatt, Mary-Ellen Taplin, Shanna Dowling, Kathleen M. Mahoney, E. Werner, Paul L. Nguyen> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Feb 23
• 15 citations
  Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model
  Dina Stroopinsky, Jessica Liegel, Manoj Bhasin, Giulia Cheloni, Beena E Thomas, Swati S. Bhasin, Ruchit Panchal, Haider Ghiasuddin, Maryam Rahimian, Myrna Nahas, Shira...> ;Haematologica. 2021 Feb 4
• 48 citations
  KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1
  Rupal S. Bhatt, Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman, Chun-Hau Chen, Opeyemi Jegede, Paul J. Catalano, Jean-Christoph...> ;Cancer Immunology Research. 2021 Feb 1
• 79 citations
  VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
  Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, Gordon J. Freeman> ;Trends in Immunology. 2021 Jan 23
• 4 citations
  The Postpartum Hemorrhage Patient Safety Bundle Implementation at a Single Institution: Successes, Failures, and Lessons Learned.
  Christina M. Duzyj, Carla Boyle, Kathleen M. Mahoney, Anna Rose Johnson, Grace Ogot, Charletta Ayers> ;American Journal of Perinatology. 2021 Oct 1
• 300 citations
  The importance of exosomal PDL1 in tumour immune evasion
  Dhouha Daassi, Kathleen M. Mahoney, Gordon J. Freeman> ;Nature Reviews. Immunology. 2020 Jan 21
• 15 citations
  Acidity changes immunology: a new VISTA pathway.
  Kathleen M. Mahoney, Gordon J. Freeman> ;Nature Immunology. 2020 Jan 1
• 8 citations
  Substance Abuse Disorder: Prenatal, Intrapartum and Postpartum Care.
  Kathleen M. Mahoney, Wendy Reich, Susan Urbanek> ;MCN. the American Journal of Maternal Child Nursing. 2019 Sep 1
• 68 citations
  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical...
  Jean-Christophe Pignon, Opeyemi Jegede, Sachet A. Shukla, David A. Braun, Christine Horak, Megan Wind-Rotolo, Yuko Ishii, Paul J. Catalano, Jonian Grosha, Abdallah Fla...> ;Clinical Cancer Research. 2019 Apr 1
• 33 citations
  Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM re...
  Mayer Fishman, Janice P. Dutcher, Joseph I. Clark, Ajjai Alva, Gerald P Miletello, Brendan Curti, Neeraj Agarwal, Ralph J. Hauke, Kathleen M. Mahoney, Helen Moon, J. T...> ;Journal for Immunotherapy of Cancer. 2019 Mar 27
• 80 citations
  A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.
  Kathleen M. Mahoney, Sachet A. Shukla, Nikolaos Patsoukis, Apoorvi Chaudhri, Edward P. Browne, Arnon Arazi, Thomas Eisenhaure, William F. Pendergraft, Ping Hua, Hung C...> ;Cancer Immunology, Immunotherapy. 2019 Mar 1
• 70 citations
  Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
  Carla Calagua, Joshua W. Russo, Yue Sun, Rachel J. Schaefer, Rosina T. Lis, Zhenwei Zhang, Kathleen M. Mahoney, Glenn J. Bubley, Massimo Loda, Mary-Ellen Taplin, Steve...> ;Clinical Cancer Research. 2017 Nov 15
• 249 citations
  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
  Jun Zhou, Kathleen M. Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra J. Lee, Xiaoyun Liao, Scott J. Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Pi...> ;Cancer Immunology Research. 2017 Jun 1
• 8 citations
  Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
  Kathleen M. Mahoney, Susanna Jacobus, Rupal S. Bhatt, Jiaxi Song, Ingrid Carvo, Su-Chun Cheng, Mekailah Simpson, Andre P. Fay, Igor Puzanov, M. Dror Michaelson, Michae...> ;Clinical Genitourinary Cancer. 2016 Aug 1
• 53 citations
  Learning from PD-1 Resistance: New Combination Strategies
  Xia Bu, Kathleen M. Mahoney, Gordon J. Freeman> ;Trends in Molecular Medicine. 2016 Jun 1
• 106 citations
  PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
  Kathleen M. Mahoney, Heather Sun, Xiaoyun Liao, Ping Hua, Marcella Callea, Edward A. Greenfield, F. Stephen Hodi, Arlene H. Sharpe, Sabina Signoretti, Scott J. Rodig, ...> ;Cancer Immunology Research. 2015 Dec 1
• 890 citations
  Combination cancer immunotherapy and new immunomodulatory targets.
  Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman> ;Nature Reviews. Drug Discovery. 2015 Aug 1
• 406 citations
  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
  Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott> ;Clinical Therapeutics. 2015 Apr 1
• 114 citations
  Prognostic and predictive markers for the new immunotherapies.
  Kathleen M. Mahoney, Michael B. Atkins> ;Oncology. 2014 Nov 11
• Join now to see all

Lectures

• A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018